8-K ·Filed Apr 23, 2026
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish
Monitor upcoming clinical trial results and regulatory developments for Annamycin, as this preclinical data could influence future investment decisions and partnership opportunities.
Final — all horizons settled through T+60d
MBRX ▼ -15.75% at T+60d
LONG call ✗ call lost -15.75% · α vs SPY -20.77% · entry $2.54 → $2.14
T+1d
0.00%
call 0.00% · α -0.78%
$2.54
settled 6mo ago
T+5d
-1.18%
call -1.18% · α -2.66%
$2.51
settled 6mo ago
T+20d
-7.87%
call -7.87% · α -12.51%
$2.34
settled 5mo ago
T+60d
-15.75%
call -15.75% · α -20.77%
$2.14
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Moleculin Biotech announced preclinical data showing its drug candidate Annamycin significantly inhibited tumor growth and extended survival in pancreatic cancer models, highlighting its potential in a major unmet medical need. The data was presented at the AACR Annual Meeting 2026.
Key Facts
- Annamycin produced significant tumor growth inhibition across multiple pancreatic ductal adenocarcinoma (PDAC) models
- Treatment extended median survival by more than 60% compared to control in a metastatic model
- Annamycin demonstrated significantly higher tumor and pancreatic tissue accumulation than doxorubicin
- The data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2026
Financial Impact
No direct financial impact disclosed
revenueeps
Risk Factors
- Preclinical data may not translate to human clinical efficacy
- The company will require significant additional financing to conduct its clinical trials
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-013083 |
| Exhibit: ex_949464.htm | 0001437749-26-013083 |
| Document: 0001437749-26-013083-index-headers.html | 0001437749-26-013083 |
| Document: 0001437749-26-013083-index.html | 0001437749-26-013083 |
| Document: 0001437749-26-013083.txt | 0001437749-26-013083 |
30 reports for MBRX
54% Hit rate @ T+20 Went positive at some point 10 of 15 best @ T+60▲ +1671.25%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 17d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 $7.09 | ▲ +1145.17% | ▲ +1145.20% | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
Showing 10 of 30
US Market Status
Market Closed — Opens Tue (< 1m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers